Safety of topical calcineurin inhibitors in atopic dermatitis: Evaluation of the evidence



Topical calcineurin inhibitors (pimecrolimus, Elidel, East Hanover, NJ; and tacrolimus, Protopic, Tokyo, Japan) have been approved for the use in atopic dermatitis since the year 2000. These compounds represent a relatively safe class of topical anti-inflammatory, nonsteroidal therapy. However, in January of 2006, the US Food and Drug Administration issued a black box warning on these compounds about possible concerns of increased long-term malignancy risk due to systemic immunosuppression. To date, studies from clinical trials, systemic absorption, and post-marketing surveillance show no evidence for this systemic immunosuppression or increased risk for any malignancy.

References and Recommended Reading

  1. 1.
    Taieb A, Hanifin J, Cooper K, et al.: Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15–17, 2005. J Allergy Clin Immunol 2006, 117:378–390.PubMedCrossRefGoogle Scholar
  2. 2.
    Grassberger M, Baumruker T, Enz A, et al.: A novel antiin flammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999, 141:264–273.PubMedCrossRefGoogle Scholar
  3. 3.
    Van Leent EJ, Ebelin ME, Burtin P, et al.: Low systemic exposure after repeated topical application of pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002, 204:63–68.PubMedCrossRefGoogle Scholar
  4. 4.
    Hultsch T, Kapp A, Spergel J: Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005, 211:174–187. In this paper, pharmacokinetics and immunologic changes from topical calcineurin inhibitors are reviewed. Also, animal cancer studies are explored.PubMedCrossRefGoogle Scholar
  5. 5.
    Wellington K, Jarvis B: Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002, 62:817–840.PubMedCrossRefGoogle Scholar
  6. 6.
    Luger T, Van Leent EJ, Graeber M, et al.: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001, 144:788–794.PubMedCrossRefGoogle Scholar
  7. 7.
    Eichenfield L, Lucky A, Boguniewicz M, et al.: Safety and Efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002, 46:495–504.PubMedCrossRefGoogle Scholar
  8. 8.
    Paller AS, Lebwohl M, Fleischer AB Jr, et al.: Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005, 52:810–822.PubMedCrossRefGoogle Scholar
  9. 9.
    Boguniewicz M, Fiedler VC, Raimer S, et al.: A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998, 102:637–644.PubMedCrossRefGoogle Scholar
  10. 10.
    Ruzicka T, Bieber T, Schopf E, F, et al.: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997, 337:816–821.PubMedCrossRefGoogle Scholar
  11. 11.
    Paller AS, McAlister RO, Doyle JJ, Jackson A: Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila) 2002, 41:323–332.CrossRefGoogle Scholar
  12. 12.
    Staab D, Kaufmann R, Brautigam M, Wahn U: Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents’ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol 2005, 16:527–533.PubMedCrossRefGoogle Scholar
  13. 13.
    Drake L, Prendergast M, Maher R, et al.: The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001, 44:S65-S72. This work shows that tacrolimus ointment significantly improves the quality of life of patients with atopic dermatitis.PubMedCrossRefGoogle Scholar
  14. 14.
    Fonacier L, Spergel J, Charlesworth EN, et al.: Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005, 115:1249–1253. An expert panel of allergists/immunologists from the American College of Allergy Asthma Immunology and the American Academy of Allergy Asthma and Immunology did a detailed review on the safety regarding the “black box” warning on topical calcineurin inhibitors.PubMedCrossRefGoogle Scholar
  15. 15.
    Novartis-Pharmeutical: Elidel prescribing information. (@#@ Package insert): 2006.Google Scholar
  16. 16.
    Astellas-Pharmaceutical: Protopic prescribing information. (@#@ Package insert): 2006.Google Scholar
  17. 17.
    Allen B, Lakhanpaul M, Morris A, et al.: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003, 88:969–973.PubMedCrossRefGoogle Scholar
  18. 18.
    Harper J, Green A, Scott G, et al.: First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001, 144:781–787.PubMedCrossRefGoogle Scholar
  19. 19.
    Harper J, Smith C, Rubins A, et al.: A multicenter study of the pharmacokinetics of tacrolimus ointment after.rst and repeated application to children with atopic dermatitis. J Invest Dermatol 2005, 124:695–699.PubMedCrossRefGoogle Scholar
  20. 20.
    Pediatric Advisory Committee Meeting of the US Food Drug Administration. ac/05/ The site provides the complete hearing of the FDA pediatric advisory committee on the topical calcineurin inhbitors.20. Novartis-Pharmaceutical. Data on .le; 2006.Google Scholar
  21. 22.
    Astellas-Pharmaceutical: Data on .le: 2006.Google Scholar
  22. 23.
    SEER cancer statistics review, 1975–2001. http://seer. Scholar
  23. 24.
    Hill DJ, Sporik R, Thorburn J, Hosking CS: The association of atopic dermatitis in infancy with immunoglobulin E food sensitization. J Pediatr 2000, 137:475–479.PubMedCrossRefGoogle Scholar
  24. 25.
    Naylor M, Elmets C, Jaracz E, Rico JM: Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatol Treat 2005, 16:149–153.CrossRefGoogle Scholar
  25. 26.
    Miller D, Weinstock M: Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1995, 30:774–778.CrossRefGoogle Scholar
  26. 27.
    Tran C, Lubbe J, Sorg O, et al.: Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005, 211:341–347.PubMedCrossRefGoogle Scholar
  27. 28.
    Papp KA, Breuer K, Meurer M, et al.: Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005, 52:247–253.PubMedCrossRefGoogle Scholar
  28. 29.
    Stiehm ER, Roberts RL, Kaplan MS, et al.: Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005, 53:S206-S213.PubMedCrossRefGoogle Scholar
  29. 30.
    Packet insert: Protopic (tacrolimus 0.03 and 0.1%) ointment. Rockville, MD: US Food and Drug Administration.Google Scholar
  30. 31.
    Wahn U, Bos JD, Goodfield M, et al.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002, 110:e2.PubMedCrossRefGoogle Scholar
  31. 32.
    Ringer Ellingsen A, Brandt Sorensen F, Overgaard Larsen J, et al.: Stereological quantification of lymphocytes in skin biopsies from atopic dermatitis patients. Acta Dermatol Venereol 2001, 81:258–262.CrossRefGoogle Scholar
  32. 33.
    Hanifin JM, Paller AS, Eichenfield L, et al.: Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005, 53:S186-S194. This paper examines the long-term safety of tacrolimus ointment, showing no significant or increased adverse effects in up to 4 years of treatment.PubMedCrossRefGoogle Scholar
  33. 34.
    Reitamo S, Ortonne JP, Sand C, et al.: A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005, 152:1282–1289.PubMedCrossRefGoogle Scholar
  34. 35.
    Paul C, Cork M, Rossi AB, et al.: Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006, 117:e118-e128. This paper examines the long-term safety of 1% pimecrolimus cream, showing no significant adverse effects in up to 2 years of treatment.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Division of Pediatric Allergy-ImmunologyUniversity of Colorado Health Sciences CenterDenverUSA

Personalised recommendations